Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.
    Difference
    0.2%
    Check dated 2026-10-20T05:49:03.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site revision displayed in the footer changes from v3.7.0 to v3.7.1, while the clinical trial record continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T08:15:00.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the expected study record content. This shows a standard error screen and site footer where study details used to appear.
    Difference
    20%
    Check dated 2026-09-22T03:28:49.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.5 to v3.6.6, indicating a minor update to the page's revision history. It does not modify the study data or the user-facing content of the page.
    Difference
    0.1%
    Check dated 2026-08-31T23:47:12.000Z thumbnail image
  6. Check
    76 days ago
    Change Detected
    Summary
    Revision: v3.6.5 replaces v3.6.4, indicating a deployment/update of the site's underlying tooling. This update does not change the study data, eligibility criteria, results, or visible content on the page.
    Difference
    0.0%
    Check dated 2026-08-10T11:58:44.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    The Study Details page updated its revision label from v3.6.3 to v3.6.4, representing a small page patch rather than new or altered study information.
    Difference
    0.0%
    Check dated 2026-07-27T05:43:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.